Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects

American Journal of Psychiatry

Volumn 153, Issue 1, 1996, Pages 83-92

  Krystal, John H ^a   Webb, Elizabeth ^b   Cooney, Ned L ^b   Kranzler, Henry R ^b   Southwick, Steven W ^b   Heninger, George R ^b   Charney, Dennis S ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALCOHOL; SODIUM CHLORIDE; YOHIMBINE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DOWN REGULATION; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEROTONINERGIC SYSTEM;

ADULT; AFFECT; ALCOHOLISM; DOUBLE-BLIND METHOD; HOSPITALIZATION; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; PIPERAZINES; PLACEBOS; PROLACTIN; SEROTONIN; SEROTONIN AGONISTS; YOHIMBINE;

EID: 0030027713     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.1.83     Document Type: Review

References (92)

1. Meyer RE: Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry 1989; 50:403-412
2. Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS: Age of alcoholism onset, II: relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry 1989; 46:231-236
3. Olsen RE, Gursey D, Vester J: Evidence for a defect in tryptophan metabolism in chronic alcoholism. N Engl J Med 1960; 263:1169-1174
4. Friedman MJ, Krstulovic AM, Severinghaus JM, Brown SJ: Altered conversion of tryptophan to kynurenine in newly abstinent alcoholics. Biol Psychiatry 1988; 23:89-93
5. Beck O, Borg S, Sedvall G: Tryptophan levels in human cerebrospinal fluid after acute and chronic ethanol consumption. Drug Alcohol Depend 1983; 12:217-222
6. Mellerup ET, Bech P, Lauritzen L, Lunde M, Plenge P: Platelet paroxetine binding in alcoholics. Alcohol Alcohol 1992; 27: 603-606
7. Daoust M, Lhuintre JP, Ernouf D, Legrand E, Breton P, Boucly P; Ethanol intake and 3H-serotonin uptake, II: a study in alcoholic patients using platelets 3H-paroxetine binding. Life Sci 1991; 48:1977-1983
8. Simonsson P, Alling C: The 5-hydroxytryptamine stimulation formation of mositol monophosphate is inhibited in platelets from alcoholics. Life Sci 1988; 42:385-391
9. Simonsson P, Berglund M, Oreland L, Moberg A-L, Alling C: Serotonin-stimulated phosphoinositide hydrolysis in platelets from post-withdrawal alcoholics. Alcohol Alcohol 1992; 27:607-612
10. Ballenger JC, Goodwin FK, Major LF, Brown GL: Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 1979; 36:224-227
11. Banki C: Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Trans 1981; 50:98-101
12. Lee MA, Meltzer HY: Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 1991; 30:1017-1030
13. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL: Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46:587-599
14. Benkelfat C, Murphy DL, Hill JL, George DT, Nutt D, Linnoila M: Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients (letter). Arch Gen Psychiatry 1991; 48:383
15. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS: Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry 1994; 51:898-911
16. 3H]-imipramine binding in the human brain post-mortem: effects of age and alcohol. J Neurochem 1988; 5:528-534
17. 3H-Paroxetine binding in brains of alcoholics. Psychiatry Res 1991; 38:293-299
18. 1A receptor binding in the human brain post-mortem: effects of age and alcohol. Brain Res 1991; 554:56-64
19. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM: Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47:490-498
20. Sellers EM, Higgins GA, Sobell MB: 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13:69-75
21. Borg S, Kvande H, Sedvall G: Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers. Science 1981; 213:1135-1137
22. Borg S, Czamecka A, Kvande H, Mossberg D, Sedvall G: Clinical conditions and concentrations of MOPEG in the cerebrospinal fluid of male alcoholic patients during withdrawal. Alcohol Clin Exp Res 1985; 9:103-108
23. Fujimoto A, Nagao T, Ebara T, Sato M, Otsuki S: Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state. Biol Psychiatry 1983; 18:1141-1152
24. Hawley JR, Major LF, Schulman EA, Linnoila M: Cerebrospinal fluid 2-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal: correlations with clinical signs. Arch Gen Psychiatry 1985; 42:1056-1062
25. Giacobini E, Izikowitz S, Wegmann A: Urinary norepinephrine and epinephrine excretion in delirium tremens. Arch Gen Psychiatry 1960; 3:289-296
26. Lubman A, Emrick C, Mosiman WF, Freedman R: Altered mood and norepinephrine metabolism following withdrawal from ethanol. Drug Alcohol Depend 1983; 12:3-13
27. Romach MK, Sellers EM: Management of the alcohol withdrawal syndrome. Annu Rev Med 1991; 42:323-340
28. Glue P, Sellman JD, Nicholls MG, Abbott R, Joyce PR, Nutt DJ: Studies of alpha-2-adrenoceptor function in abstinent alcoholics. Br J Addiction 1989; 84:97-102
29. Balldin J, Berggren U, Engel J, Lindstedt G, Sundkler A, Wålinder J: Alpha-2-adrenoceptor sensitivity in early alcohol withdrawal. Biol Psychiatry 1992; 312:712-719
30. Tran VT, Snyder SH, Major LF, Hawley RJ: GABA receptors in brains of alcoholics. Ann Neurol 1981; 38:289-292
31. Spitzer RL, Williams JBW, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624-629
32. Selzer M: The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127:1653-1658
33. von Knorring AL, Bohman M, von Knorring L, Oreland L: Platelet MAO activity as a biological marker in subgroups of alcoholism. Acta Psychiatr Scand 1985; 72:51-58
34. Lamparski DM, Roy A, Nutt DJ, Linnoila M: The criteria of Cloninger et al and von Knorring et al for subgrouping alcoholics: a comparison in a clinical population. Acta Psychiatr Scand 1991; 84:497-502
35. Cooney NL, Kadden RM, Litt MD: A comparison of methods for assessing sociopathy in male and female alcoholics. J Stud Alcohol 1990; 51:42-48
36. Gough HG (ed): CPI Administrator's Guide. Palo Alto, Calif, Consulting Psychologists Inventory Press, 1987
37. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS: Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:266-274
38. Southwick SM, Krystal JH, Morgan A, Nagy LM, Dan E, Johnson D, Bremner D, Charney DS: Yohimbine and m-chlorophenylpiperazine in PTSD, in New Research Program and Abstracts, 144th Annual Meeting of the American Psychiatric Association. Washington, DC, APA, 1991
39. Keane TM, Caddell JM, Taylor KL: Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. J Consult Clin Psychol 1988; 56:85-90
40. Morgan CA, Southwick SM, Grillon CM, Nagy LM, Davis M, Krystal JH, Charney DS: Yohimbine enhancement of the acoustic startle response. Psychopharmacology (Berl) 1993; 110:342-347
41. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR: Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992; 86:273-282
42. Charney DS, Woods SW, Goodman WK, Heninger GR: Serotonin function in anxiety, II: effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987; 92:14-24
43. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS: m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 1993; 50:624-635
44. Krystal JH, McDougle CJ, Woods SW, Price LH, Heninger GR, Charney DS: Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl) 1992; 108:313-319
45. Krystal JH, Morgan CA, Webb E, Cooney N, Grillon C, Davis M, Southwick S, Kranzler H, Charney DS: Acoustic startle in alcoholics and healthy subjects (abstract). Alcohol Clin Exp Res 1992; 16:233
46. Maas JW, Hattox SE, Landis DH, Roth RH: The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyplienethyleneglycol (MHPG). Brain Res 1976; 118:167-173
47. Gagnon J, Roth JM, Carroll M, Hofmann R, Haycock KA, Plamondon J, Feldman DS Jr, Simpson J: SuperANOVA: Accessible General Linear Modeling. Berkeley, Calif, Abacus Concepts, 1989
48. Wolf WA, Kuhn DM: The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int 1991; 19:39-44
49. 1 recognition sites. J Recept Res 1988; 8:59-81
50. Hamik A, Peroutka SJ: 1-(m-chlorophenyl)piperazine interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25:569-575
51. 3 serotonin receptors: results of a structure-affinity study. Eur J Pharmacol 1989; 168:387-392
52. 1B receptor ligands exist? Arch Pharmacol 1989; 339: 675-683
53. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR: Molecular cloning and expression of a 5-hydroxytryptamine- subtype. J Biol Chem 1993; 268:18200-18204
54. 1C) receptors. J Pharmacol Exp Ther 1987; 242:552-557
55. 2 receptors in interneurons. Synapse 1991; 9:208-218
56. 2-activated interneuron. Brain Res 1990; 506:62-69
57. Ireland SJ, Tyers MB: Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol 1987; 90:229-238
58. 3 receptors. Life Sci 1992; 50:599-605
59. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS: Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991; 38:227-236
60. Murphy DL, Lesch KP, Aulakh CS, Pigott TA III: Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 1991; 43:527-552
61. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR: Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988; 45:177-185
62. Mueller EA, Murphy DL, Sunderland T: Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl) 1986; 89:388-391
63. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR: Noradrenergic dysregulation in panic disorder, in Neurobiology of Panic Disorder. Edited by Ballenger JC. New York, Wiley-Liss, 1990, pp 91-105
64. Redmond DE Jr: New and old evidence for the involvement of a brain norepinephrine system in anxiety, in The Phenomenology and Treatment of Anxiety. Edited by Fann WE. New York, Plenum, 1979, pp 153-203
65. van Oene JC, de Vries JB, Horn AS: The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo. Naunyn Schmeidebergs Arch Pharmacol 1984; 327:304-311
66. 1D binding sites in human brain membranes. Synapse 1989; 3:61-66
67. Halbreich U, Castaneda R, Galanter M, Mandola R, Sharpless N: Plasma MHPG and age in detoxified alcoholics. Biol Psychiatry 1990; 27:626-630
68. 2-Adrenergic receptor function in depression: the cortisol response to yohimbine. Arch Gen Psychiatry 1986; 43:849-858
69. al-Damluji S: Adrenergic mechanisms in the control of corticotrophin secretion. J Endocrinol 1988; 119:5-14
70. Linnoila M, Mefford I, Nutt D, Adinoff B: Alcohol withdrawal and noradrenergic function. Ann Intern Med 1987; 107:875-889
71. Pile A, Enna SJ: Antidepressant administration has a differential effect on rat brain alpha-adrenoceptor sensitivity to agonists and antagonists. Eur J Pharmacol 1986; 132:277-282
72. Rudolf CD, Kaplan SL, Ganong WF: Sites at which clonidine acts to affect blood pressure and the secretion of renin, growth hormone and ACTH. Neuroendocrinology 1980; 31:121-128
73. Terry LC, Martin JB: Evidence for α-adrenergic regulation of episodic growth hormone and prolactin secretion in the undisturbed male rat. Endocrinology 1981; 108:1869-1873
74. Vescovi PP, Pedrazzoni M, Michelini M, Maninetti L, Passeri M: Impaired PRL response to hypothermia in alcoholic men. Neuropeptides 1992; 22:205-207
75. al-Damluji S, Francis D: Activation of central alpha 1-adrenoceptors in humans stimulates secretion of prolactin and TSH, as well as TSH. Am J Physiol 1993; 264(2, part 1):E208-E214
76. Berria M, Pau KY, Spies HG: Evidence for alpha 1-adrenergic involvement in neuropeptide Y-stimulated GNRH release in female rabbits. Neuroendocrinology 1991; 53:480-486
77. Balldin J, Alling C, Gottfries CG, Lindstedt G, Langstrom G: Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology (Berl) 1985; 86:142-146
78. 2 receptor function in alcoholism. Drug Alcohol Depend 1993; 32:159-162
79. Balldin JI, Berggren UC, Lindstedt G: Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcohol Clin Exp Res 1992; 16:71-74
80. Adinoff B, Risher-Flowers D, De Jong J, Ravitz B, Bone GHA, Nutt DJ, Roehrich L, Martin PR, Linnoila M: Disturbances of hypothalamic-pituitary-adrenal axis functioning during ethanol withdrawal in six men. Am J Psychiatry 1991; 148:1023-1025
81. Targum SD, Wheadon DE, Chastek CT, McCabe WJ, Advani MT: Dysregulation of hypothalamic-pituitary-adrenal axis function in depressed alcoholic patients. J Affect Disord 1982; 4: 347-353
82. Rees LH, Besser GM, Jeffcoate WJ: Alcohol-induced pseudo-Cushing's syndrome. Lancet 1977; 1:726-728
83. Magraf HW, Moyer CA, Ashford LE, Lavalle LW: Adrenocortical function in alcoholics. J Surg Res 1967; 7:55-62
84. Adinoff B, Martin PR, Bone GHA, Eckardt MJ, Roehrich L, George DT, Moss HB, Eskay R, Linnoila M, Gold PW: Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin releasing hormone and corticotropin levels in alcoholics after recent and long-term abstinence. Arch Gen Psychiatry 1990; 47:325-330
85. von Bardeleben U, Heuser I, Holsboer F: Human CRH stimulation response during acute withdrawal and after medium-term abstention from alcohol use. Psychoneuroendocrinology 1989; 14:441-449
86. Heuser I, von Bardeleben U, Boll E, Holsboer F: Response of ACTH and cortisol to human corticotropin-releasing hormone after short-term abstention from alcohol abuse. Biol Psychiatry 1988; 24:316-321
87. Bailly D, Dewailly D, Beuscart R, Couplet G, Dumont P, Racadot A, Fossati P, Parquet PJ: Adrenocorticotropin and cortisol responses to ovine corticotropin-releasing factor in alcohol dependence disorder: preliminary report. Horm Res 1989; 31:72-75
88. Errico AL, Parsons OA, King AC, Lovallo WR: Attenuated cortisol response to biobehavioral stressors in sober alcoholics. J Stud Alcohol 1993; 54:393-398
89. Halbreich U, Castaneda R, Galanter M: Low basal levels of cortisol distinguish detoxified alcoholics with major depressive disorder from non-MDDs. Alcohol Clin Exp Res 1989; 13:834-836
90. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214
91. Roy A, Virkkunen M, Linnoila M: Reduced central serotonin turnover in a subgroup of alcoholics? Prog Neuropsychopharmacol Biol Psychiatry 1987; 11:173-177
92. Petrakis I, Webb E, Abi-Dargham A, Cooney N, Charney DS, Krystal JH: Serotonin contributions to cue-induced craving in alcoholics (abstract). Alcohol Clin Exp Res 1993; 17:335